Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders

Expert Review of Anticancer Therapy

Volumn 11, Issue 3, 2011, Pages 403-414

  Spivak, Jerry L ^a   Hasselbalch, Hans ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

acute leukemia; essential thrombocythemia; hydroxycarbamide; polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA; PIPOBROMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALOPECIA; ARTERY THROMBOSIS; BLEEDING; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS; CELL PROLIFERATION; CHILL; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; LEG ULCER; LIVER FUNCTION TEST; LONG TERM CARE; LOW DRUG DOSE; MACULOPAPULAR RASH; MEGALOCYTOSIS; MOUTH ULCER; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; PNEUMONIA; POLYCYTHEMIA VERA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN ATROPHY; SKIN CARCINOMA; SKIN DISEASE; SKIN ULCER; STOMACH PAIN; THROMBOCYTHEMIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VEIN THROMBOSIS; VOMITING; XEROSIS;

ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; FEMALE; FERTILITY; HUMANS; HYDROXYUREA; MALE; MYELOPROLIFERATIVE DISORDERS;

EID: 79952980528     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.10     Document Type: Review

References (99)

1. Dressler W, Stein R. [About Justus Liebig's hydroxylurea]. Ann. Chem. Pharm. 150, 242-252 (1869)
2. Rosenthal F, Wislicki L. [About the relationship between the most lethal blood poisons and degradation products of proteins: a contribution to the etiology of pernicious anemia]. Kollek. Klin. Wochenschr. 7, 972-977 (1928)
3. Stearns B, Losee KA, Bernstein J. Hydroxyurea a new type of potential antitumor agent. J. Med. Chem. 6, 201 (1963)
4. Stock CC, Clarke DA, Philips FS, et al. Sarcoma 180 screening data. Cancer Res. 20(5 Pt 2), 193-381 (1960)
5. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin. Oncol. 19(3 Suppl. 9), 11-19 (1992)
6. Stevens MR. Hydroxyurea: an overview. J. Biol. Regul. Homeost. Agents 13(3), 172-175 (1999)
7. Rodriguez GI, Kuhn JG, Weiss GR, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 91(5), 1533-1541 (1998) (Pubitemid 28110316)
8. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet. 34(5), 347-358 (1998) (Pubitemid 28192905)
9. Yan JH, Ataga K, Kaul S, et al. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J. Clin. Pharmacol. 45(4), 434-445 (2005) (Pubitemid 40490416)
10. Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 28(8), 1559-1565 (1968)
11. Moore EC, Hurlbert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Pharmacol. Ther. 27(2), 167-196 (1985) (Pubitemid 15037812)
12. Szekeres T, Fritzer-Szekeres M, Elford HL. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit. Rev. Clin. Lab. Sci. 34(6), 503-528 (1997) (Pubitemid 28043734)
13. Yarbro JW. Mechanism of action of hydroxyurea. Semin. Oncol. 19(3 Suppl. 9), 1-10 (1992)
14. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J. Neurosurg. 86(5), 845-852 (1997) (Pubitemid 27187688)
15. Kramer OH, Knauer SK, Zimmermann D, et al. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27(6), 732-740 (2008) (Pubitemid 351186315)
16. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266(5186), 801-805 (1994) (Pubitemid 24359288)
17. Van den Berg C, Von Hoff DD. Use of hydroxyurea to alter drug resistance of human tumor cells. Cancer Treat. Res. 78, 95-114 (1995)
18. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353(1), 33-45 (2005) (Pubitemid 41007805)
19. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 111(2), 231-239 (2003) (Pubitemid 36105922)
20. Hehlmann R. Current CML therapy: progress and dilemma. Leukemia 17(6), 1010-1012 (2003) (Pubitemid 36733475)
21. Frame D. Chronic myeloid leukemia: standard treatment options. Am. J. Health Syst. Pharm. 63(23 Suppl. 8), S10-S14, quiz S21-S22 (2006) (Pubitemid 44846180)
22. Silver RT. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia 19(1), 39-43 (2005) (Pubitemid 40090074)
23. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 114(1), 26-40 (2005) (Pubitemid 40911570)
24. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N. Engl. J. Med. 304(8), 441-447 (1981) (Pubitemid 11178999)
25. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin. Hematol. 34(1), 17-23 (1997) (Pubitemid 27063138)
26. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 332(17), 1132-1136 (1995)
27. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501), 1945-1953 (2005) (Pubitemid 41713984)
28. Kessler CM, Klein HG, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br. J. Haematol. 50(1), 157-167 (1982) (Pubitemid 12168677)
29. Palandri F, Catani L, Testoni N, et al. Long-term follow-up of consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am. J. Hematol. 84(4), 215-220 (2009)
30. Budde U, Scharf RE, Franke P, et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82(6), 1749-1757 (1993) (Pubitemid 23278765)
31. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90(9), 3370-3377 (1997) (Pubitemid 27473405)
32. Emadi A, Spivak JL. Anagrelide: 20 years later. Expert Rev. Anticancer Ther. 9(1), 37-50 (2009)
33. Barbui T, Carobbio A, Rambaldi A, et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 114(4), 759-763 (2009)
34. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 109(9), 4105 (2007) (Pubitemid 46641767)
35. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon?a?2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8), 3065-3072 (2008)
36. Larsen TS, Bjerrum OW, Pallisgaard N, et al. Sustained major molecular response on interferon a?2b in two patients with polycythemia vera. Ann. Hematol. 87(10), 847-850 (2008)
37. Girodon F, Schaeffer C, Cleyrat C, et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617Fpositive patients within the first years of hydroxyurea therapy. Haematologica 93(11), 1723-1727 (2008)
38. Ricksten A, Palmqvist L, Johansson P, et al. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 93(8), 1260-1261 (2008)
39. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108, 3913-3915 (2006) (Pubitemid 44864576)
40. Larsen TS, Pallisgaard N, de Stricker K, et al. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology 14(1), 11-15 (2009)
41. Ruggeri M, Tosetto A, Frezzato M, et al. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann. Intern. Med. 139(6), 470-475 (2003)
42. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 108(7), 2493-2494 (2006) (Pubitemid 44497538)
43. Randi ML, Ruzzon E, Tezza F, et al. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 16(3-4), 181-184 (2005) (Pubitemid 40910906)
44. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur. J. Haematol. 41(4), 375-381 (1988) (Pubitemid 19003754)
45. Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21(2), 277-280 (2007) (Pubitemid 46158120)
46. Lannemyr O, Kutti J. Hydroxyurea as a cause of drug fever in essential thrombocythaemia. Eur. J. Haematol. 62(5), 354-355 (1999) (Pubitemid 29232267)
47. Hallam MJ, Kolesar JM. Hydroxyurea induced acute elevations in liver function tests. J. Oncol. Pharm. Pract. 14(1), 61-63 (2008)
48. Gilbert HS. Modern treatment strategies in polycythemia vera. Semin. Hematol. 40(1 Suppl. 1), 26-29 (2003) (Pubitemid 36403121)
49. Kojima K, Fujii N, Omoto E, et al. Cyclic thrombocytopenia and polycythemia vera. Ann. Hematol. 82(1), 61-63 (2003) (Pubitemid 36700975)
50. Tefferi A, Elliott MA, Kao PC, et al. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood 96(4), 1582-1584 (2000) (Pubitemid 30658494)
51. Burthem J, Chaudhry MS. Hydroxycarbamide associated platelet count oscillations in a patient with polycythaemia vera. A case report and review of the literature. Platelets 19(3), 234-235 (2008) (Pubitemid 351574451)
52. Tauscher J, Siegel F, Petrides P. Hydroxyurea induced oscillations in twelve patients with polycythemia vera. Haematologica 95(7), 1227-1229 (2010)
53. Dumont-Wallon G, Milpied-Homsi B, Morineau N, et al. Effets secondaires cutanéomuqueux de l?hydroxyurée: étude prospective sur 27 patients. Hematologie 12(4), 262-266 (2006) (Pubitemid 44623621)
54. Zaccaria E, Cozzani E, Parodi A. Secondary cutaneous effects of hydroxyurea: possible pathogenetic mechanisms. J. Dermatol. Treat. 17(3), 176-178 (2006) (Pubitemid 44147838)
55. Jeevankumar B, Thappa DM. Blue lunula due to hydroxyurea. J. Dermatol. 30(8), 628-630 (2003) (Pubitemid 37071288)
56. Young HS, Khan AS, Kendra JR, et al. The cutaneous side-effects of hydroxyurea. Clin. Lab. Haematol. 22(4), 229-232 (2000)
57. Best PJ, Petitt RM. Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin. Proc. 73(10), 961-963 (1998) (Pubitemid 28467697)
58. Jain V, Gupta K, Nagpal N. Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls. J. Coll. Physicians Surg. Pak. 15(10), 658-660 (2005) (Pubitemid 43173643)
59. Kalambokis G, Stefanou D, Arkoumani E, et al. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-a and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur. J. Haematol. 73(1), 67-70 (2004) (Pubitemid 38824193)
60. Wong CC, Brown D, Howling SJ, et al. Hydroxyurea-induced pneumonitis in a patient with chronic idiopathic myelofibrosis after prolonged drug exposure. Eur. J. Haematol. 71(5), 388-390 (2003) (Pubitemid 37330512)
61. Martinez A, Hinz JM, Gómez L, et al. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat. Res. 656(1-2), 1-7 (2008)
62. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat. Rev. Cancer 8, 24-36 (2008)
63. Collins AR, Squires S, Johnson RT. Inhibitors of repair DNA synthesis. Nucleic Acids Res. 10(4), 1203-1213 (1982)
64. Finazzi G, Ruggeri M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br. J. Haematol. 110(3), 577-583 (2000)
65. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am. J. Hematol. 74(1), 26-31 (2003) (Pubitemid 37040191)
66. Bernasconi P, Boni M, Cavigliano PM, et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 16(10), 2078-2083 (2002) (Pubitemid 35203451)
67. Merlat A, Lai JL, Sterkers Y, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 13(2), 250-257 (1999) (Pubitemid 29092658)
68. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91(2), 616-622 (1998) (Pubitemid 28053386)
69. Marusyk A, Wheeler LJ, Mathews CK, et al. p53 mediates senescence-like arrest induced by chronic replicational stress. Mol. Cell Biol. 27(15), 5336-5351 (2007) (Pubitemid 47124389)
70. Gottifredi V, Shieh S, Taya Y, et al. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc. Natl Acad. Sci. USA 98(3), 1036-1041 (2001) (Pubitemid 32121182)
71. Marusyk A, DeGregori J. Replicational stress selects for p53 mutation. Cell Cycle 6(17), 2148-2151 (2007) (Pubitemid 47450416)
72. Lundin C, Erixon K, Arnaudeau C, et al. Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol. Cell Biol. 22(16), 5869-5878 (2002) (Pubitemid 34815835)
73. Saintigny Y, Delacote F, Vares G, et al. Characterization of homologous recombination induced by replication inhibition in mammalian cells. EMBO J. 20(14), 3861-3870 (2001) (Pubitemid 32694383)
74. Bertrand P, Saintigny Y, Lopez BS. p53's double life: transactivationindependent repression of homologous recombination. Trends Genet. 20(6), 235-243 (2004) (Pubitemid 38625681)
75. Bilousova G, Marusyk A, Porter CC, et al. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol. 3(12), e401 (2005)
76. Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 68(17), 6884-6888 (2008)
77. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112(4), 1402-1412 (2008)
78. Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost. 32(4 Pt 2), 417-421 (2006)
79. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 21(2), 270-276 (2007) (Pubitemid 46158119)
80. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1), 375-379 (2007) (Pubitemid 47026857)
81. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108(10), 3548-3555 (2006)
82. Spivak JL. An inconvenient truth. Blood 115(14), 2727-2728 (2010)
83. Hanft VN, Fruchtman SR, Pickens CV, et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 95(11), 3589-3593 (2000) (Pubitemid 30428496)
84. Evenson DP, Jost LK. Hydroxyurea exposure alters mouse testicular kinetics and sperm chromatin structure. Cell Prolif. 26(2), 147-159 (1993) (Pubitemid 23125366)
85. Ficsor G, Ginsberg LC. The effect of hydroxyurea and mitomycin C on sperm motility in mice. Mutat. Res. 70(3), 383-387 (1980) (Pubitemid 10141855)
86. Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin. Oncol. 9(1), 84-94 (1982) (Pubitemid 12116289)
87. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 93, 988-993 (2008) (Pubitemid 351957015)
88. Ferm V. Severe developmental malformations: malformations induced by urethane and hydroxyurea in the hamster. Arch. Pathol. 81, 174-177 (1966)
89. Wilson JG, Scott WJ, Ritter EJ, et al. Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology 11(2), 169-178 (1975)
90. Cinkotai KI, Wood P, Donnai P, et al. Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion. J. Clin. Pathol. 47(8), 769-770 (1994)
91. Delmer A, Rio B, Bauduer F, et al. Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br. J. Haematol. 82(4), 783-784 (1992) (Pubitemid 23011997)
92. Doney KC, Kraemer KG, Shepard TH. Combination chemotherapy for acute myelocytic leukemia during pregnancy: three case reports. Cancer Treat. Rep. 63(3), 369-371 (1979) (Pubitemid 9192237)
93. Sylvester RK, Lobell M, Teresi ME, et al. Excretion of hydroxyurea into milk. Cancer 60(9), 2177-2178 (1987) (Pubitemid 17153479)
94. Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch. Dermatol. 111(2), 183-187 (1975)
95. Tatarski I, Sharon R. Management of polycythemia vera with hydroxyurea Semin. Hematol. 34(10), 24-28 (1997) (Pubitemid 27063139)
96. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105(7), 2664-2670 (2005) (Pubitemid 40446255)
97. Abdulkarim K, Girodon F, Johansson P, et al. AML transformation in 56 patients with Ph-MPD in two well defined populations. Eur. J. Haematol. 82(2), 106-111 (2009)
98. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 88(1), 13-18 (2003) (Pubitemid 36168849)
99. Radaelli F, Onida F, Rossi FG, et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with longterm follow-up from a single institution. Hematology 13(4), 195-202 (2008)